THE ROLE OF METABOLIC SYNDROME IN THE DEVELOPMENT OF  COLORECTAL CANCER

ZVIAD MAGLAPHERIDZE; VERA KAPETIVADZE; REVAZ TABUKASHVILI; TAMAR LAZASHVILI; IRINA KAPETIVADZE

doi:10.52340/jecm.2023.06.18

THE ROLE OF METABOLIC SYNDROME IN THE DEVELOPMENT OF COLORECTAL CANCER

Authors

ZVIAD MAGLAPHERIDZE Tbilisi State Medical University
VERA KAPETIVADZE Tbilisi State Medical University
REVAZ TABUKASHVILI Tbilisi State Medical University
TAMAR LAZASHVILI Tbilisi State Medical University
IRINA KAPETIVADZE Tbilisi State Medical University

DOI:

https://doi.org/10.52340/jecm.2023.06.18

Keywords:

Colorectal cancer, Metabolic Syndrome, Insulin Resistance, Obesity, Dyslipidemia

Abstract

Objective. The aim of our study was to determine the role of metabolic syndrome (MetS) and its cluster in the development of colorectal cancer (CRC).

Methods. 50 patients with the CRC diagnosis have been included in the study group (age 40-65 years). 50 conditionally healthy persons selected in the control group. The parameters determined during study fulfillment were: fasting and postprandial plasma glucose, fasting C-peptide and insulin, IGF and IGFBP3, HOMA indices, lipid spectrum, anthropometric parameters, blood pressure. MetS was defined by the IDF definition criteria. Obtained results were statistically treated by the soft SPSS23.0.

Results. Obesity defined by body mass, BMI, and waist circumference was significantly more expressed in the study group (p<0.001). The levels of IGF and IGFBP3 in the study group were significantly differ compared to controls (p<0.001). Same pattern was obtained during study of carbohydrate homeostasis and insulin resistance. No significant difference was revealed between the values of blood pressure, creatinine and lipid metabolism (except HDL-C) in both groups. MetS were established for 37 patients (74%) in the study group, and 22 persons (44%) of the controls (Сhi2=9.21, p=0.002). Correlation analysis has shown significant association between the number of MetS features and CRC development (r=0.425, p<0.001).

Conclusions. MetS, IGF-1, FPG, PPG, insulin resistance, and the degree of obesity was positively associated with CRC development; and insulin sensitivity and IGFBP3 was negatively correlated with CRC development. It should definitely be noted, the risk of CRC development was positively correlated with the number of MetS features. Therefore, first of all the disappear of these modifiable risk factors by lifestyle changes and subsequent measures plays the crucial role in the CRC prevention.

Downloads

Download data is not yet available.

References

Lillich F.F., Imig J.D., Proschak E. Multi-Target Approaches in Metabolic Syndrome. Front. Pharmacol. 2021;11:554961.

Esposito K., Chiodini P., Capuano A. et al. Giugliano D. Colorectal cancer association with metabolic syndrome and its components: A systematic review with meta-analysis. Endocrine. 2013;44:634–647.

Hu J., Liu X., Chi J. et al. Expressions of IGF-1. ERK. GLUT4. IRS-1 in metabolic syndrome complicated with colorectal cancer and their associations with the clinical characteristics of CRC. Cancer Biomark. 2018;21:883–891.

Crawley D.J., Holmberg L., Melvin J.C. et al. Serum glucose and risk of cancer: A meta-analysis. BMC Cancer. 2014;14:985.

Yamada K., Araki S., Tamura M. et al. Relation of serum total cholesterol. serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ. Int. J. Epidemiol. 1998;27:794–798.

Schoen R.E., Tangen C.M., Kuller L.H. et al. Increased blood glucose and insulin. body size. and incident colorectal cancer. J. Natl. Cancer Inst. 1999;91:1147–11454. doi: 10.1093/jnci/91.13.1147.

Chung Y.W., Han D.S., Park Y.K. et al. Association of obesity. serum glucose and lipids with the risk of advanced colorectal adenoma and cancer: A case-control study in Korea. Dig. Liver Dis. 2006; 38:668–672.

Limburg P.J., Stolzenberg-Solomon R.Z., Vierkant R.A. et al. Insulin. glucose. insulin resistance. and incident colorectal cancer in male smokers. Clin. Gastroenterol. Hepatol. 2006;4:1514–1521.

Gunter M.J., Hoover D.R., Yu H. et al. Insulin. insulin-like growth factor-I. endogenous estradiol. and risk of colorectal cancer in postmenopausal women. Cancer Res. 2008;68:329–337.

Kabat G.C., Kim M.Y., Strickler H.D. et al. A longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopausal women. Br. J. Cancer. 2012;106:227–232.

Vulcan A., Manjer J., Ohlsson B. High blood glucose levels are associated with higher risk of colon cancer in men: A cohort study. BMC Cancer. 2017;17:842.

Xu J., Ye Y., Wu H. et al. Association between markers of glucose metabolism and risk of colorectal cancer. BMJ Open. 2016;6:e011430.

Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart. Lung. and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120: 1640-1645.

Jin EH, Han K, Lee DH et al. Association Between Metabolic Syndrome and the Risk of Colorectal Cancer Diagnosed Before Age 50 Years According to Tumor Location. GI Cancer, 2022, 163(3):P637-648.

Ma Y, Yang Y, Wang F et al. Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One. 2013; 8e53916.

Hofseth LJ, Hebert JR, Chanda A et al. Early-onset colorectal cancer: initial clues and current views. Nat Rev Gastroenterol Hepatol. 2020; 17: 352-364.

Jochem C, Leitzmann M. Obesity and colorectal cancer. Recent Results Cancer Res. 2016; 208: 17-41.

Song M, Chan AT. Environmental factors, gut microbiota, and colorectal cancer prevention. Clin Gastroenterol Hepatol. 2019; 17: 275-289.

Choi YJ, Lee DH, Han KD et al. Abdominal obesity, glucose intolerance and decreased high-density lipoprotein cholesterol as components of the metabolic syndrome are associated with the development of colorectal cancer. Eur J Epidemiol. 2018; 33: 1077-1085.

Chen H, Zheng X, Zong X et al. Metabolic syndrome, metabolic comorbid conditions and risk of early-onset colorectal cancer. Gut. 2021; 70: 1147-1154.

Stocks T, Lukanova A, Johansson M et al. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obesity. 2008; 32: 304-314.